These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35023271)
1. Rapid onset of response to sonidegib for multiple facial basal cell carcinomas during COVID-19 pandemic. Trabelsi S; Khidher F Dermatol Ther; 2022 Apr; 35(4):e15317. PubMed ID: 35023271 [No Abstract] [Full Text] [Related]
2. Complete remission of an advanced basal cell carcinoma after only 3-month treatment with sonidegib: Report of a case and drug management during COVID-19 pandemic. Villani A; Fabbrocini G; Costa C; Scalvenzi M Dermatol Ther; 2020 Nov; 33(6):e14200. PubMed ID: 32870541 [No Abstract] [Full Text] [Related]
3. Dermatoscopy and locally advanced or multiple basal cell carcinomas: a non-invasive tool to evaluate sonidegib effectiveness. Conforti C; Toffoli L; Agozzino M; Di Meo N; Zelin E; Zalaudek I Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755992 [No Abstract] [Full Text] [Related]
4. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas. Villani A; Fabbrocini G; Costa C; Potestio L; Scalvenzi M Oncologist; 2022 Jun; 27(6):e533. PubMed ID: 35436344 [No Abstract] [Full Text] [Related]
5. Rapid and exceptional response to Sonidegib in a patient with multiple locally advanced basal cell carcinomas. Tarantino V; Zavattaro E; Veronese F; Gironi LC; Savoia P Anticancer Drugs; 2021 Apr; 32(4):465-468. PubMed ID: 33534224 [TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced basal cell carcinoma with sonidegib: perspective from the 30-month update of the BOLT trial. Chen L; Aria AB; Silapunt S; Lee HH; Migden MR Future Oncol; 2018 Mar; 14(6):515-525. PubMed ID: 29119833 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months. Dummer R; Lear JT; Guminski A; Leow LJ; Squittieri N; Migden M J Am Acad Dermatol; 2021 Apr; 84(4):1162-1164. PubMed ID: 33358380 [No Abstract] [Full Text] [Related]
9. The safety and efficacy of sonidegib for the treatment of locally advanced basal cell carcinoma. Collier NJ; Ali FR; Lear JT Expert Rev Anticancer Ther; 2016 Oct; 16(10):1011-8. PubMed ID: 27636236 [TBL] [Abstract][Full Text] [Related]
10. Effective management of infiltrative locally advanced basal cell carcinoma of the tibia with sonidegib. Venturi F; Lambertini M; Melotti B; De Paolis M; Dika E Int J Dermatol; 2024 May; 63(5):685-687. PubMed ID: 38351632 [No Abstract] [Full Text] [Related]
11. Anal and rectal locally advanced basal cell carcinoma treated with sonidegib. Conforti C; Toffoli L; Degrassi F; di Meo N; Zalaudek I Dermatol Ther; 2022 Feb; 35(2):e15242. PubMed ID: 34854197 [No Abstract] [Full Text] [Related]
12. Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Chen L; Silapunt S; Migden MR Future Oncol; 2016 Sep; 12(18):2095-105. PubMed ID: 27189494 [TBL] [Abstract][Full Text] [Related]
13. Giant basal cell carcinoma of the vulva successfully treated with Sonidegib. Camela E; Villani A; Scalvenzi M; Costa C Dermatol Ther; 2022 Sep; 35(9):e15723. PubMed ID: 35851517 [No Abstract] [Full Text] [Related]
14. Clinical Clearance Following Improvement of Histologic Subtype of Basal Cell Carcinoma with Sonidegib. Leow LJ; Howard V Acta Derm Venereol; 2022 Nov; 102():adv00809. PubMed ID: 36281813 [No Abstract] [Full Text] [Related]
15. Neoadjuvant treatment of basosquamous carcinomas with Sonidegib: An innovative approach. Dika E; Melotti B; Comito F; Tassone D; Baraldi C; Campione E; Mussi M; Venturi F Exp Dermatol; 2023 Nov; 32(11):2038-2039. PubMed ID: 37432021 [No Abstract] [Full Text] [Related]
16. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial. Migden MR; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kudchadkar R; Trefzer U; Gogov S; Pallaud C; Yi T; Mone M; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Chang AL; Cornélis F; Lear JT; Sellami D; Dummer R Lancet Oncol; 2015 Jun; 16(6):716-28. PubMed ID: 25981810 [TBL] [Abstract][Full Text] [Related]
17. An exploratory open-label, investigator-initiated study to evaluate the efficacy and safety of combination sonidegib and buparlisib for advanced basal cell carcinomas. Tran DC; Moffat A; Brotherton R; Pague A; Zhu GA; Chang ALS J Am Acad Dermatol; 2018 May; 78(5):1011-1013.e3. PubMed ID: 29175429 [No Abstract] [Full Text] [Related]
18. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib. Danial C; Sarin KY; Oro AE; Chang AL Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616 [TBL] [Abstract][Full Text] [Related]
19. Sonidegib in a patient with multiple basal cell carcinomas and HIV infection. Hoffmann V; Husak R; Maiwirth F; Sasama B; Zahn A; Guski S; Peitsch WK J Dtsch Dermatol Ges; 2021 Apr; 19(4):592-594. PubMed ID: 33448149 [No Abstract] [Full Text] [Related]
20. Sonidegib (Odomzo) for basal cell carcinoma. Med Lett Drugs Ther; 2016 Feb; 58(1489):31-2. PubMed ID: 26938701 [No Abstract] [Full Text] [Related] [Next] [New Search]